reported that gut microbiota-derived metabolites alter estrogen receptor activity and endocrine therapy responsiveness in ER+ BC, and targeting metabolic pathways through diet or drugs could be useful to improve endocrine therapy efficacy in the clinic (104). The gene discussed is ESR1; the disease is breast cancer.